362 related articles for article (PubMed ID: 25203311)
21. Terlipressin in hepatorenal syndrome.
Mazur JE; Cooper TB; Dasta JF
Ann Pharmacother; 2011 Mar; 45(3):380-7. PubMed ID: 21386023
[TBL] [Abstract][Full Text] [Related]
22. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial.
Goyal O; Sidhu SS; Sehgal N; Puri S
J Assoc Physicians India; 2016 Sep; 64(9):30-35. PubMed ID: 27762512
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
Carter JA; Huang X; Jamil K; Corman S; Ektare V; Niewoehner J
J Med Econ; 2023; 26(1):1342-1348. PubMed ID: 37729445
[TBL] [Abstract][Full Text] [Related]
24. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials.
Serpa Neto A; Nassar AP; Cardoso SO; Manetta JA; Pereira VG; Espósito DC; Damasceno MC; Russell JA
Crit Care; 2012 Aug; 16(4):R154. PubMed ID: 22889256
[TBL] [Abstract][Full Text] [Related]
25. Terlipressin in hepatorenal syndrome: Evidence for present indications.
Rajekar H; Chawla Y
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
[TBL] [Abstract][Full Text] [Related]
26. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
[TBL] [Abstract][Full Text] [Related]
27. Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
Huang X; Bindra J; Chopra I; Niewoehner J; Wan GJ
Adv Ther; 2023 Dec; 40(12):5432-5446. PubMed ID: 37812332
[TBL] [Abstract][Full Text] [Related]
28. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
[TBL] [Abstract][Full Text] [Related]
29. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K;
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
[TBL] [Abstract][Full Text] [Related]
30. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
31. Hepatorenal syndrome: the clinical impact of vasoactive therapy.
Colle I; Laterre PF
Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):173-188. PubMed ID: 29258378
[TBL] [Abstract][Full Text] [Related]
32. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis.
Dobre M; Demirjian S; Sehgal AR; Navaneethan SD
Int Urol Nephrol; 2011 Mar; 43(1):175-84. PubMed ID: 20306131
[TBL] [Abstract][Full Text] [Related]
33. COST EFFECTIVENESS OF USING TERLIPRESSIN TO TREAT HEPATORENAL SYNDROME.
Ferreira LM; Terrabuio DR; Ferreira CM; Mazo DFC; Haddad LBP
Arq Gastroenterol; 2022; 59(2):268-274. PubMed ID: 35830040
[TBL] [Abstract][Full Text] [Related]
34. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
Muñoz LE; Alcalá EG; Cordero P; Martínez MA; Vázquez NY; Galindo S; Mendoza E; Segura JJ
Ann Hepatol; 2009; 8(3):207-11. PubMed ID: 19841499
[TBL] [Abstract][Full Text] [Related]
35. Terlipressin for hepatorenal syndrome.
Gluud LL; Kjaer MS; Christensen E
Cochrane Database Syst Rev; 2006 Oct; (4):CD005162. PubMed ID: 17054242
[TBL] [Abstract][Full Text] [Related]
36. Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials.
Sridharan K; Sivaramakrishnan G
J Gen Intern Med; 2018 Jan; 33(1):97-102. PubMed ID: 28924736
[TBL] [Abstract][Full Text] [Related]
37. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.
Singh V; Ghosh S; Singh B; Kumar P; Sharma N; Bhalla A; Sharma AK; Choudhary NS; Chawla Y; Nain CK
J Hepatol; 2012 Jun; 56(6):1293-8. PubMed ID: 22322237
[TBL] [Abstract][Full Text] [Related]
38. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
[TBL] [Abstract][Full Text] [Related]
39. Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis.
Thomson MJ; Taylor A; Sharma P; Lok AS; Tapper EB
Dig Dis Sci; 2020 May; 65(5):1539-1548. PubMed ID: 31571102
[TBL] [Abstract][Full Text] [Related]
40. Terlipressin for hepatorenal syndrome.
Wong F
Curr Opin Gastroenterol; 2024 May; 40(3):156-163. PubMed ID: 38353275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]